Meta-hlorofenilpiperazin

Iz Wikipedije, slobodne enciklopedije
(Preusmjereno sa Metahlorofenilpiperazin)
Idi na navigaciju Idi na pretragu
meta-Hlorofenilpiperazin
(IUPAC) ime
1-(3-hlorofenil)piperazin
Klinički podaci
Identifikatori
CAS broj 6640-24-0
ATC kod nije dodeljen
PubChem[1][2] 1355
ChemSpider[3] 1314
ChEBI CHEBI:10588 YesY
ChEMBL[4] CHEMBL478 YesY
Hemijski podaci
Formula C10H13ClN2 
Mol. masa 196,676 g/mol
SMILES eMolekuli & PubHem
Farmakokinetički podaci
Metabolizam Hepatic
Poluvreme eliminacije 2-6 sata
Izlučivanje Renalno
Farmakoinformacioni podaci
Trudnoća ?
Pravni status
Način primene Oralno, nazalno, rektalno

meta-Hlorofenilpiperazin (mCPP) je psihoaktivni lek iz fenilpiperazinske klase. On je razvijen krajem 1970-tih i korišten je u naučnim istraživanjima, pre nego što je postao dezijnirana droga sredinom 2000-tih.[5][6] mCPP je detektovan u pilulama koje su reklamirane kao legalne alternative za nedopuštne stimulanse u Novom Zelandu i u pilulama koje su prodavane kao "ekstazi" u Evropi i Sjedinjenim Državama.[7][8]

Uprkos pokušaja da se uvede u upotrebu kao rekreaciona supstanca, mCPP se zapravo generalno smatra nepoželjnim jer proizvodi neprijatna iskustva.[7] Njemu nedostaju potkrepljujući efekti,[9] proizvodi depresivne i anksiogene efekte kod glodara i ljudi,[10][11] i može da indukuje panične napade kod osoba koje su im podložne.[12][13][14][15] On takođe pogoršava opsesivno-kompulzivne simptome kod ljudi sa tim poremećajem.[16][17][18]

Vidi još[uredi - уреди | uredi kôd]

References[uredi - уреди | uredi kôd]

  1. ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737.  edit
  2. ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. http://www.jcheminf.com/content/2/1/3.  edit
  4. ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  5. ↑ Bossong MG, Van Dijk JP, Niesink RJ (December 2005). „Methylone and mCPP, two new drugs of abuse?”. Addiction Biology 10 (4): 321–3. DOI:10.1080/13556210500350794. PMID 16318952. http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1355-6215&date=2005&volume=10&issue=4&spage=321. 
  6. ↑ Lecompte Y, Evrard I, Arditti J (2006). „[Metachlorophenylpiperazine (mCPP): a new designer drug]” (French). Thérapie 61 (6): 523–30. PMID 17348609. 
  7. ↑ 7,0 7,1 Bossong M, Brunt T, Van Dijk J, et al. (March 2009). „mCPP: an undesired addition to the ecstasy market”. Journal of Psychopharmacology (Oxford, England) 24 (9): 1395–401. DOI:10.1177/0269881109102541. PMID 19304863. http://jop.sagepub.com/cgi/pmidlookup?view=long&pmid=19304863. 
  8. ↑ Vogels N, Brunt TM, Rigter S, van Dijk P, Vervaeke H, Niesink RJ (December 2009). „Content of ecstasy in the Netherlands: 1993-2008”. Addiction (Abingdon, England) 104 (12): 2057–66. DOI:10.1111/j.1360-0443.2009.02707.x. PMID 19804461. http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0965-2140&date=2009&volume=104&issue=12&spage=2057. 
  9. ↑ Tancer M, Johanson CE (October 2003). „Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP”. Drug and Alcohol Dependence 72 (1): 33–44. DOI:10.1016/S0376-8716(03)00172-8. PMID 14563541. http://linkinghub.elsevier.com/retrieve/pii/S0376871603001728. 
  10. ↑ Rajkumar R, Pandey DK, Mahesh R, Radha R (April 2009). „1-(m-Chlorophenyl)piperazine induces depressogenic-like behaviour in rodents by stimulating the neuronal 5-HT(2A) receptors: proposal of a modified rodent antidepressant assay”. European Journal of Pharmacology 608 (1-3): 32–41. DOI:10.1016/j.ejphar.2009.02.041. PMID 19269287. http://linkinghub.elsevier.com/retrieve/pii/S0014-2999(09)00198-8. 
  11. ↑ Kennett GA, Whitton P, Shah K, Curzon G (May 1989). „Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists”. European Journal of Pharmacology 164 (3): 445–54. DOI:10.1016/0014-2999(89)90252-5. PMID 2767117. 
  12. ↑ Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW (November 1991). „Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects”. Biological Psychiatry 30 (10): 973–84. DOI:10.1016/0006-3223(91)90119-7. PMID 1756202. 
  13. ↑ Charney DS, Woods SW, Goodman WK, Heninger GR (1987). „Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects”. Psychopharmacology 92 (1): 14–24. PMID 3110824. 
  14. ↑ Van Veen JF, Van der Wee NJ, Fiselier J, Van Vliet IM, Westenberg HG (October 2007). „Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy controls”. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology 17 (10): 637–42. DOI:10.1016/j.euroneuro.2007.03.005. PMID 17481859. http://linkinghub.elsevier.com/retrieve/pii/S0924-977X(07)00082-X. 
  15. ↑ van der Wee NJ, Fiselier J, van Megen HJ, Westenberg HG (October 2004). „Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine in patients with panic disorder and controls”. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology 14 (5): 413–7. DOI:10.1016/j.euroneuro.2004.01.001. PMID 15336303. http://linkinghub.elsevier.com/retrieve/pii/S0924977X0400015X. 
  16. ↑ Hollander E, DeCaria CM, Nitescu A, et al. (January 1992). „Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers”. Archives of General Psychiatry 49 (1): 21–8. PMID 1728249. http://archpsyc.ama-assn.org/cgi/pmidlookup?view=long&pmid=1728249. [mrtav link]
  17. ↑ Broocks A, Pigott TA, Hill JL, et al. (June 1998). „Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results”. Psychiatry Research 79 (1): 11–20. DOI:10.1016/S0165-1781(98)00029-8. PMID 9676822. http://linkinghub.elsevier.com/retrieve/pii/S0165178198000298. 
  18. ↑ Pigott TA, Zohar J, Hill JL, et al. (March 1991). „Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder”. Biological Psychiatry 29 (5): 418–26. DOI:10.1016/0006-3223(91)90264-M. PMID 2018816. 

Spoljašnje veze[uredi - уреди | uredi kôd]

Portal Medicina
Portal Hemija


Izvor: https://sh.wikipedia.org/w/index.php?title=Meta-hlorofenilpiperazin&oldid=41150345